Natural Capsules Q1 FY27: Capsules stability, API scale-up, and a pragmatic HPMC reset

/n# Natural Capsules Q1 FY27: Capsules stability, API scale-up, and a pragmatic HPMC reset/n/nNatural Capsules Limited (NCL) entered FY27 with a quarter that looks weaker on the surface but carries a few important operational markers underneath. For Q1 FY27, consolidated revenue from operations stood at 48.71 crore, down 17 percent quarter-on-quarter but up 8 percent year-on-year. EBITDA was 1.12 crore, translating to an EBITDA margin of 2.30 percent excluding other income. Profit after tax was a loss of 5.74 crore, and EPS was negative at 5.55./n/nManagement framed the quarter as operationally stronger than the headline comparison suggests. The preceding quarter had benefited from dispatch of deferred inventory following the Puducherry plant shutdown. In addition, a new ERP implementation towards the end of Q1 briefly disrupted billing and dispatch, pushing sales from the final five days of the quarter into Q2. In other words, Q1’s reported revenue carries a timing dent, while Q4 carried a one-off uplift./n/n## Capsules business: demand intact, pricing improving, and costs passed through/n/nThe capsules segment remains the company’s core business. NCL positions itself as a hard capsule shell manufacturer that pioneered vegetarian capsules in India and is the second largest Indian manufacturer of gelatin capsules. It operates two manufacturing facilities in Bengaluru and Pondicherry, with installed capacity of 20.25 billion capsules per annum in FY26./n/nDuring Q1 FY27, management reported sustained demand across capsule products alongside improved realizations. A key operational positive was the ability to navigate rising input costs through timely pass-throughs to customers. The commentary also highlighted that gelatin capsules delivered healthy margins, and management expressed confidence in sustaining that profitability through the remainder of the year./n/nThe quarter also captured a currency benefit. Management stated that depreciation of the Indian rupee provided a meaningful tailwind to export realizations. Exports were 28.94 percent of revenue in FY26, and the presentation shows the export mix skewed towards Asia, followed by Africa and the Americas. The company exports to 28 countries across five continents./n/nAt the same time, the consolidated margin profile remains thin. Even after an improved year-on-year EBITDA, the Q1 FY27 EBITDA margin excluding other income was 2.30 percent. That low operating margin, combined with sizable depreciation and rising finance costs, continues to weigh on bottom-line performance./n/n### Financial snapshot (consolidated)/n/n| Metric | Q1 FY26 | Q4 FY26 | Q1 FY27 | QoQ | YoY |/n|---|---:|---:|---:|---:|---:|/n| Revenue from Operations (crore) | 45.20 | 58.45 | 48.71 | -17% | 8% |/n| EBITDA (crore) | 0.32 | 1.33 | 1.12 | -16% | 251% |/n| EBITDA Margin excl Other Income | 0.71% | 2.28% | 2.30% | 2 bps | 159 bps |/n| Finance Cost (crore) | 2.53 | 2.89 | 4.97 | 72% | 97% |/n| PAT (crore) | -5.58 | -4.98 | -5.74 | 15% | 3% |/n/n## HPMC: market uncertainty drives a capacity reallocation/n/nA meaningful strategic decision in Q1 was the company’s response to weakness in the HPMC capsule segment. Management described the US demand environment as erratic, with continued uncertainty around duty structures. With no material US export volumes during the quarter, NCL decided to temporarily convert one HPMC line into a gelatin line to protect capacity utilization and overall profitability. A second HPMC line is expected to be similarly converted in the coming month./n/nThis is a clear example of operational course correction. Rather than running underutilized assets, the company chose to redirect capacity to a product line where demand and profitability were more stable. The trade-off is that HPMC’s near-term growth is being deprioritized until the US market becomes more predictable./n/n## API business: mixed quarter, but concrete technical and commercial milestones/n/nNCL’s longer-term re-rating narrative rests on the API segment being developed under its subsidiary, Natural Biogenex Private Limited (NBPL). The company is building a steroidal API portfolio including prednisolone, betamethasone, dexamethasone, hydrocortisone, and derivative salts. The presentation states that commercial production for large volume batches began in March 2026 and highlights that the greenfield facility at Tumkur is being set up with compliance targets aligned to WHO GMP, USFDA, and EU GMP guidelines, with a zero liquid discharge design./n/nQ1 FY27 was described as mixed for APIs. Management cited geopolitical uncertainty as a headwind. It also pointed to currency movement as a specific challenge for African exports routed through merchant exporters, with an appreciating Chinese yuan and a depreciating Indian rupee affecting volumes in that channel./n/nDespite the near-term pressure, the quarter included several milestones that matter for execution tracking:/n/nFirst, the first batch under a contract manufacturing agreement with Fermbox Bio commenced in August, which management described as an important milestone. Second, the company executed a new contract manufacturing agreement with a Mumbai-based client, expanding its CMO pipeline. Third, there were technical advances that directly target unit economics. Management stated it completed a prednisolone batch at batch-scale and expects to produce its first fully backward-integrated prednisolone batch by the end of September. It also reported that one fermentation step has been successfully transitioned to an enzymatic route, resulting in improved yields and cost optimization./n/nRegulatory progress and leadership strengthening were also highlighted. The WHO GMP application process has been initiated, with the associated audit expected by the end of Q2 FY27. Additionally, the company appointed a Chief Operating Officer for the API business with over 30 years of industry experience, including a prior stint at Shilpa Medicare./n/n## PLI incentive: a visible support lever for the API scale-up plan/n/nThe presentation reiterates the Production Linked Incentive (PLI) scheme context and positions it as a de-risking factor for the API investment cycle. NCL states it has three approvals under the PLI scheme for steroidal APIs and expects to receive an incentive of around 67 crore over six years. For fermentation-based products, the scheme provides incentives across FY25 to FY30 at specified rates by year buckets, as presented in the deck./n/nWhile the incentive is not a substitute for sustainable operating performance, it can provide meaningful support during scale-up years when fixed costs, regulatory spending, and working capital requirements can weigh on reported profitability./n/n## Takeaways from Q1 FY27/n/nNatural Capsules’ Q1 FY27 reflects a company navigating two realities at once. The capsules business is showing steady demand and improving realizations, with management emphasizing cost pass-through and margin resilience in gelatin capsules. At the same time, the consolidated profit profile remains pressured due to thin operating margins and elevated finance costs and depreciation./n/nOn strategy, the quarter stands out for practical decision-making. The temporary conversion of HPMC lines to gelatin signals a willingness to prioritize utilization and profitability when end-market conditions turn uncertain. And in APIs, the company is beginning to show measurable execution markers: contract manufacturing activity starting, backward integration moving towards a defined near-term milestone, process yield improvements, and a stated timeline for a WHO GMP audit./n/nThe next few quarters will likely be judged on three things that management itself called out: sustaining profitability in capsules, scaling API volumes, and progressing regulatory milestones. Q1 offered early signs on all three, but the numbers also underline that execution needs to translate into stronger consolidated margins to change the earnings trajectory./n